The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Resident of Manitoba
Age, 6 - 24 years
Diagnosis of major depressive disorder (MDD), anxiety disorder, or obsessive-compulsive disorder (OCD)
Current or past history of selective serotonin reuptake inhibitor (SSRI), e.g., Citalopram [Celexa], Escitalopram [Cipralex], Fluoxetine [Prozac], Fluvoxamine [Luvox], Sertraline [Zoloft], Paroxetine [Paxil/Plaxil CR]) therapy
Inability of parent/legal guardian/mature minors to give informed consent
Inability of the child (6 - 13 years) to give informed assent
Unwillingness of the child to provide a saliva sample for genetic analysis
Current, past, or suspected diagnosis of attention deficit hyperactivity disorder (combined or hyperactive type), oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, pervasive developmental disorder
University of Manitoba
Lead sponsor
Health Sciences Centre Foundation, Manitoba
Collaborator
Children's Hospital Research Institute of Manitoba
Collaborator
University of Calgary
Collaborator